Findings indicate that the expression of GCDFP-15 is observed in various breast cancer subtypes, with higher prevalence in hormone receptor (HR)-positive and HER2-positive tumors, while its expression is relatively low in the triple-negative breast cancer (TNBC) subtype. Here, ERBB2 is linked to breast cancer.